Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Rhea-AI Summary

Aytu BioPharma, Inc. announced its CEO, Josh Disbrow, will participate in the Emerging Growth Conference, presenting on April 4, 2024, at 4:40 p.m. Eastern time. The webcast will update attendees on the company's commercial progress.

Webcasted presentation to take place at 4:40 p.m. Eastern time

DENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference.

Mr. Disbrow will present on Thursday, April 4, 2024, at 4:40 p.m. Eastern time. A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed HERE.

During the event, Mr. Disbrow will update participants on Aytu's commercial progress made since his last presentation to participants at the Emerging Growth Conference in December 2023.

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on www.EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.

Management will also host one-on-one investor meetings after the conference presentation. To request a virtual one-on-one meeting with the Aytu management team, please contact your respective Emerging Growth Conference representative or email the Company's investor relations team at aytu@lythampartners.com.

About Aytu BioPharma, Inc.

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.

Contacts for Investors

Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com

Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

View the original press release on accesswire.com

FAQ

When will Josh Disbrow present at the Emerging Growth Conference?

Josh Disbrow will present on Thursday, April 4, 2024, at 4:40 p.m. Eastern time.

Where can the webcast link be found?

The webcast link can be found on the investor relations page of Aytu BioPharma's website or accessed through the provided link.

Will there be an archived webcast available?

Yes, an archived webcast will be available on www.EmergingGrowth.com and the Emerging Growth YouTube Channel.

How can investors request a one-on-one meeting with Aytu management?

Investors can request a virtual one-on-one meeting by contacting their respective Emerging Growth Conference representative or emailing the Company's investor relations team.